NKore BioTherapeutics, Inc. announces the successful completion of its pre-IND meeting with the FDA
FDA feedback provided regulatory direction as NKore advances NK101 toward a U.S. IND submission and future US clinical trials in cancer LOS ANGELES, CA, UNITED STATES, October 1, 2026 /EINPresswire.com/ -- NKore BioTherapeutics, Inc. (" …